News
Results from Qu Biologics' Crohn's Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of ...
A further limitation of BBB research is the methodology used to measure brain exposure of biologics ... aim of capillary depletion is to remove blood vessels from brain homogenate in order ...
Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of ...
Results from Qu Biologics' Crohn's Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) — Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback